Analyzing the role of ACE2 , AR , MX1 and TMPRSS2 genetic markers for COVID-19 severity

Background The use of molecular biomarkers for COVID-19 remains unconclusive. The application of a molecular biomarker in combination with clinical ones that could help classifying aggressive patients in first steps of the disease could help clinician and sanitary system a better management of the disease. Here we characterize the role of ACE2, AR, MX1, ERG, ETV5 and TMPRSS2 for trying a better classification of COVID-19 through knowledge of the disease mechanisms. Methods A total of 329 blood samples were genotyped in ACE2 , MX1 and TMPRSS2 . RNA analyses were also performed from 258 available samples using quantitative polymerase chain reaction for genes: ERG, ETV5, AR, MX1, ACE2, and TMPRSS2. Moreover, in silico analysis variant effect predictor, ClinVar, IPA, DAVID, GTEx, STRING and miRDB database was also performed. Clinical and demographic data were recruited from all participants following WHO classification criteria. Results We confirm the use of ferritin ( p < 0.001), D-dimer ( p < 0.010), CRP ( p < 0.001) and LDH ( p < 0.001) as markers for distinguishing mild and severe cohorts. Expression studies showed that MX1 and AR are significantly higher expressed in mild vs severe patients ( p < 0.05). ACE2 and TMPRSS2 are involved in the same molecular process of membrane fusion ( p = 4.4 × 10 –3 ), acting as proteases ( p = 0.047). Conclusions In addition to the key role of TMPSRSS2 , we reported for the first time that higher expression levels of AR are related with a decreased risk of severe COVID-19 disease in females. Moreover, functional analysis demonstrates that ACE2, MX1 and TMPRSS2 are relevant markers in this disease. Graphical abstract